HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cosmetic Ingredient Use Under Feinstein Bill; Where Does CIR Come In?

This article was originally published in The Rose Sheet

Executive Summary

Whereas previous industry-backed legislation would have made final Cosmetic Ingredient Review safety determinations de facto FDA requirements unless the agency concluded differently, CIR would play a less conspicuous role in national cosmetics oversight under the proposed Personal Care Products Safety Act. Meanwhile, manufacturers would be required to file ingredient statements with FDA and attest to product safety, with opportunities for FDA to rebut their assertions and even suspend their distribution activities.

You may also be interested in...



Former FDA Cosmetics Director Weighs In On Senator Hatch's Draft FCSMA

Under the draft FDA Cosmetic Safety and Modernization Act, a product could be deemed adulterated "regardless of whether it is known which particular substance or substances may render the cosmetic injurious." EAS Consulting Group's John Bailey offers his perspective on the provision and the overall bill in an exchange with the Rose Sheet.

CIR Director Gill Steps Down, Leaving Legacy Of Improved Transparency

Lillian Gill, director of the Cosmetic Ingredient Review, helped to bolster CIR’s international reputation during her four-year stint leading the group. CIR’s profile has risen as a result of her leadership, openness to outside stakeholder input and increased public interest in cosmetic ingredients’ safety overall.

PCPC Hatching Proposal For CIR Role In FDA Ingredient Review

The Personal Care Products Council has a vision for marrying the Cosmetic Ingredient Review’s expertise with FDA’s authority, which it hopes to package into reform legislation expected this year. While FDA has balked at formalizing CIR’s role under previous proposals, this one was inspired by a third-party review program for medical devices, making it potentially more palatable to the agency and lawmakers.

Related Content

UsernamePublicRestriction

Register

RS019460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel